The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Human Respiratory Syncytial Virus Drugs-Global Market Insights and Sales Trends 2024
Synopsis
Human respiratory syncytial virus (HRSV) is a syncytial virus that causes respiratory tract infections. It is a major cause of lower respiratory tract infections and hospital visits during infancy and childhood. A prophylactic medication, palivizumab, can be employed to prevent HRSV in preterm (under 35 weeks gestation) infants, infants with certain congenital heart defects (CHD) or bronchopulmonary dysplasia (BPD), and infants with congenital malformations of the airway. Treatment is limited to supportive care, including oxygen therapy and more advanced breathing support with CPAP or nasal high flow oxygen.
The global Human Respiratory Syncytial Virus Drugs market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Human Respiratory Syncytial Virus Drugs in various end use industries. The expanding demands from the Clinical Diagnostic, Laboratories Physicians' Office and Laboratories Hospitals,, are propelling Human Respiratory Syncytial Virus Drugs market. Approved Drugs, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Off-Label Drugs segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Human Respiratory Syncytial Virus Drugs, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Human Respiratory Syncytial Virus Drugs market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Human Respiratory Syncytial Virus Drugs market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Human Respiratory Syncytial Virus Drugs sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Human Respiratory Syncytial Virus Drugs covered in this report include AstraZeneca, AbbVie, GSK and Teva Pharmaceutical, etc.
The global Human Respiratory Syncytial Virus Drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
AstraZeneca
AbbVie
GSK
Teva Pharmaceutical
Global Human Respiratory Syncytial Virus Drugs market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Human Respiratory Syncytial Virus Drugs market, Segment by Type:
Approved Drugs
Off-Label Drugs
Global Human Respiratory Syncytial Virus Drugs market, by Application
Clinical Diagnostic
Laboratories Physicians' Office
Laboratories Hospitals
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Human Respiratory Syncytial Virus Drugs manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Human Respiratory Syncytial Virus Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Human respiratory syncytial virus (HRSV) is a syncytial virus that causes respiratory tract infections. It is a major cause of lower respiratory tract infections and hospital visits during infancy and childhood. A prophylactic medication, palivizumab, can be employed to prevent HRSV in preterm (under 35 weeks gestation) infants, infants with certain congenital heart defects (CHD) or bronchopulmonary dysplasia (BPD), and infants with congenital malformations of the airway. Treatment is limited to supportive care, including oxygen therapy and more advanced breathing support with CPAP or nasal high flow oxygen.
The global Human Respiratory Syncytial Virus Drugs market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Human Respiratory Syncytial Virus Drugs in various end use industries. The expanding demands from the Clinical Diagnostic, Laboratories Physicians' Office and Laboratories Hospitals,, are propelling Human Respiratory Syncytial Virus Drugs market. Approved Drugs, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Off-Label Drugs segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Human Respiratory Syncytial Virus Drugs, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Human Respiratory Syncytial Virus Drugs market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Human Respiratory Syncytial Virus Drugs market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Human Respiratory Syncytial Virus Drugs sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Human Respiratory Syncytial Virus Drugs covered in this report include AstraZeneca, AbbVie, GSK and Teva Pharmaceutical, etc.
The global Human Respiratory Syncytial Virus Drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
AstraZeneca
AbbVie
GSK
Teva Pharmaceutical
Global Human Respiratory Syncytial Virus Drugs market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Human Respiratory Syncytial Virus Drugs market, Segment by Type:
Approved Drugs
Off-Label Drugs
Global Human Respiratory Syncytial Virus Drugs market, by Application
Clinical Diagnostic
Laboratories Physicians' Office
Laboratories Hospitals
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Human Respiratory Syncytial Virus Drugs manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Human Respiratory Syncytial Virus Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Index1 Human Respiratory Syncytial Virus Drugs Market Overview
1.1 Human Respiratory Syncytial Virus Drugs Product Overview
1.2 Human Respiratory Syncytial Virus Drugs Market Segment by Type
1.2.1 Approved Drugs
1.2.2 Off-Label Drugs
1.3 Global Human Respiratory Syncytial Virus Drugs Market Size by Type
1.3.1 Global Human Respiratory Syncytial Virus Drugs Market Size Overview by Type (2018-2029)
1.3.2 Global Human Respiratory Syncytial Virus Drugs Historic Market Size Review by Type (2018-2023)
1.3.3 Global Human Respiratory Syncytial Virus Drugs Forecasted Market Size by Type (2024-2029)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America Human Respiratory Syncytial Virus Drugs Sales Breakdown by Type (2018-2023)
1.4.2 Europe Human Respiratory Syncytial Virus Drugs Sales Breakdown by Type (2018-2023)
1.4.3 Asia-Pacific Human Respiratory Syncytial Virus Drugs Sales Breakdown by Type (2018-2023)
1.4.4 Latin America Human Respiratory Syncytial Virus Drugs Sales Breakdown by Type (2018-2023)
1.4.5 Middle East and Africa Human Respiratory Syncytial Virus Drugs Sales Breakdown by Type (2018-2023)
2 Global Human Respiratory Syncytial Virus Drugs Market Competition by Company
2.1 Global Top Players by Human Respiratory Syncytial Virus Drugs Sales (2018-2023)
2.2 Global Top Players by Human Respiratory Syncytial Virus Drugs Revenue (2018-2023)
2.3 Global Top Players by Human Respiratory Syncytial Virus Drugs Price (2018-2023)
2.4 Global Top Manufacturers Human Respiratory Syncytial Virus Drugs Manufacturing Base Distribution, Sales Area, Product Type
2.5 Human Respiratory Syncytial Virus Drugs Market Competitive Situation and Trends
2.5.1 Human Respiratory Syncytial Virus Drugs Market Concentration Rate (2018-2023)
2.5.2 Global 5 and 10 Largest Manufacturers by Human Respiratory Syncytial Virus Drugs Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Human Respiratory Syncytial Virus Drugs as of 2022)
2.7 Date of Key Manufacturers Enter into Human Respiratory Syncytial Virus Drugs Market
2.8 Key Manufacturers Human Respiratory Syncytial Virus Drugs Product Offered
2.9 Mergers & Acquisitions, Expansion
3 Human Respiratory Syncytial Virus Drugs Status and Outlook by Region
3.1 Global Human Respiratory Syncytial Virus Drugs Market Size and CAGR by Region: 2018 VS 2022 VS 2029
3.2 Global Human Respiratory Syncytial Virus Drugs Historic Market Size by Region
3.2.1 Global Human Respiratory Syncytial Virus Drugs Sales in Volume by Region (2018-2023)
3.2.2 Global Human Respiratory Syncytial Virus Drugs Sales in Value by Region (2018-2023)
3.2.3 Global Human Respiratory Syncytial Virus Drugs Sales (Volume & Value) Price and Gross Margin (2018-2023)
3.3 Global Human Respiratory Syncytial Virus Drugs Forecasted Market Size by Region
3.3.1 Global Human Respiratory Syncytial Virus Drugs Sales in Volume by Region (2024-2029)
3.3.2 Global Human Respiratory Syncytial Virus Drugs Sales in Value by Region (2024-2029)
3.3.3 Global Human Respiratory Syncytial Virus Drugs Sales (Volume & Value), Price and Gross Margin (2024-2029)
4 Global Human Respiratory Syncytial Virus Drugs by Application
4.1 Human Respiratory Syncytial Virus Drugs Market Segment by Application
4.1.1 Clinical Diagnostic
4.1.2 Laboratories Physicians' Office
4.1.3 Laboratories Hospitals
4.2 Global Human Respiratory Syncytial Virus Drugs Market Size by Application
4.2.1 Global Human Respiratory Syncytial Virus Drugs Market Size Overview by Application (2018-2029)
4.2.2 Global Human Respiratory Syncytial Virus Drugs Historic Market Size Review by Application (2018-2023)
4.2.3 Global Human Respiratory Syncytial Virus Drugs Forecasted Market Size by Application (2024-2029)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America Human Respiratory Syncytial Virus Drugs Sales Breakdown by Application (2018-2023)
4.3.2 Europe Human Respiratory Syncytial Virus Drugs Sales Breakdown by Application (2018-2023)
4.3.3 Asia-Pacific Human Respiratory Syncytial Virus Drugs Sales Breakdown by Application (2018-2023)
4.3.4 Latin America Human Respiratory Syncytial Virus Drugs Sales Breakdown by Application (2018-2023)
4.3.5 Middle East and Africa Human Respiratory Syncytial Virus Drugs Sales Breakdown by Application (2018-2023)
5 North America Human Respiratory Syncytial Virus Drugs by Country
5.1 North America Human Respiratory Syncytial Virus Drugs Historic Market Size by Country
5.1.1 North America Human Respiratory Syncytial Virus Drugs Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
5.1.2 North America Human Respiratory Syncytial Virus Drugs Sales in Volume by Country (2018-2023)
5.1.3 North America Human Respiratory Syncytial Virus Drugs Sales in Value by Country (2018-2023)
5.2 North America Human Respiratory Syncytial Virus Drugs Forecasted Market Size by Country
5.2.1 North America Human Respiratory Syncytial Virus Drugs Sales in Volume by Country (2024-2029)
5.2.2 North America Human Respiratory Syncytial Virus Drugs Sales in Value by Country (2024-2029)
6 Europe Human Respiratory Syncytial Virus Drugs by Country
6.1 Europe Human Respiratory Syncytial Virus Drugs Historic Market Size by Country
6.1.1 Europe Human Respiratory Syncytial Virus Drugs Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
6.1.2 Europe Human Respiratory Syncytial Virus Drugs Sales in Volume by Country (2018-2023)
6.1.3 Europe Human Respiratory Syncytial Virus Drugs Sales in Value by Country (2018-2023)
6.2 Europe Human Respiratory Syncytial Virus Drugs Forecasted Market Size by Country
6.2.1 Europe Human Respiratory Syncytial Virus Drugs Sales in Volume by Country (2024-2029)
6.2.2 Europe Human Respiratory Syncytial Virus Drugs Sales in Value by Country (2024-2029)
7 Asia-Pacific Human Respiratory Syncytial Virus Drugs by Region
7.1 Asia-Pacific Human Respiratory Syncytial Virus Drugs Historic Market Size by Region
7.1.1 Asia-Pacific Human Respiratory Syncytial Virus Drugs Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2029
7.1.2 Asia-Pacific Human Respiratory Syncytial Virus Drugs Sales in Volume by Region (2018-2023)
7.1.3 Asia-Pacific Human Respiratory Syncytial Virus Drugs Sales in Value by Region (2018-2023)
7.2 Asia-Pacific Human Respiratory Syncytial Virus Drugs Forecasted Market Size by Region
7.2.1 Asia-Pacific Human Respiratory Syncytial Virus Drugs Sales in Volume by Region (2024-2029)
7.2.2 Asia-Pacific Human Respiratory Syncytial Virus Drugs Sales in Value by Region (2024-2029)
8 Latin America Human Respiratory Syncytial Virus Drugs by Country
8.1 Latin America Human Respiratory Syncytial Virus Drugs Historic Market Size by Country
8.1.1 Latin America Human Respiratory Syncytial Virus Drugs Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
8.1.2 Latin America Human Respiratory Syncytial Virus Drugs Sales in Volume by Country (2018-2023)
8.1.3 Latin America Human Respiratory Syncytial Virus Drugs Sales in Value by Country (2018-2023)
8.2 Latin America Human Respiratory Syncytial Virus Drugs Forecasted Market Size by Country
8.2.1 Latin America Human Respiratory Syncytial Virus Drugs Sales in Volume by Country (2024-2029)
8.2.2 Latin America Human Respiratory Syncytial Virus Drugs Sales in Value by Country (2024-2029)
9 Middle East and Africa Human Respiratory Syncytial Virus Drugs by Country
9.1 Middle East and Africa Human Respiratory Syncytial Virus Drugs Historic Market Size by Country
9.1.1 Middle East and Africa Human Respiratory Syncytial Virus Drugs Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
9.1.2 Middle East and Africa Human Respiratory Syncytial Virus Drugs Sales in Volume by Country (2018-2023)
9.1.3 Middle East and Africa Human Respiratory Syncytial Virus Drugs Sales in Value by Country (2018-2023)
9.2 Middle East and Africa Human Respiratory Syncytial Virus Drugs Forecasted Market Size by Country
9.2.1 Middle East and Africa Human Respiratory Syncytial Virus Drugs Sales in Volume by Country (2024-2029)
9.2.2 Middle East and Africa Human Respiratory Syncytial Virus Drugs Sales in Value by Country (2024-2029)
10 Company Profiles
10.1 AstraZeneca
10.1.1 AstraZeneca Company Information
10.1.2 AstraZeneca Introduction and Business Overview
10.1.3 AstraZeneca Human Respiratory Syncytial Virus Drugs Sales, Revenue and Gross Margin (2018-2023)
10.1.4 AstraZeneca Human Respiratory Syncytial Virus Drugs Products Offered
10.1.5 AstraZeneca Recent Development
10.2 AbbVie
10.2.1 AbbVie Company Information
10.2.2 AbbVie Introduction and Business Overview
10.2.3 AbbVie Human Respiratory Syncytial Virus Drugs Sales, Revenue and Gross Margin (2018-2023)
10.2.4 AbbVie Human Respiratory Syncytial Virus Drugs Products Offered
10.2.5 AbbVie Recent Development
10.3 GSK
10.3.1 GSK Company Information
10.3.2 GSK Introduction and Business Overview
10.3.3 GSK Human Respiratory Syncytial Virus Drugs Sales, Revenue and Gross Margin (2018-2023)
10.3.4 GSK Human Respiratory Syncytial Virus Drugs Products Offered
10.3.5 GSK Recent Development
10.4 Teva Pharmaceutical
10.4.1 Teva Pharmaceutical Company Information
10.4.2 Teva Pharmaceutical Introduction and Business Overview
10.4.3 Teva Pharmaceutical Human Respiratory Syncytial Virus Drugs Sales, Revenue and Gross Margin (2018-2023)
10.4.4 Teva Pharmaceutical Human Respiratory Syncytial Virus Drugs Products Offered
10.4.5 Teva Pharmaceutical Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Human Respiratory Syncytial Virus Drugs Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Human Respiratory Syncytial Virus Drugs Industrial Chain Analysis
11.4 Human Respiratory Syncytial Virus Drugs Market Dynamics
11.4.1 Human Respiratory Syncytial Virus Drugs Industry Trends
11.4.2 Human Respiratory Syncytial Virus Drugs Market Drivers
11.4.3 Human Respiratory Syncytial Virus Drugs Market Challenges
11.4.4 Human Respiratory Syncytial Virus Drugs Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Human Respiratory Syncytial Virus Drugs Distributors
12.3 Human Respiratory Syncytial Virus Drugs Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
